[1] Asher DM, Gregori L. Human transmissible spongiform encephalopathies: historic view. Handb Clin Neurol, 2018; 153, 1−17.
[2] Watts JC, Bourkas MEC, Arshad H. The function of the cellular prion protein in health and disease. Acta Neuropathol, 2018; 135, 159−78. doi:  10.1007/s00401-017-1790-y
[3] Weissmann C, Flechsig E. PrP knock-out and PrP transgenic mice in prion research. Br Med Bull, 2003; 66, 43−60. doi:  10.1093/bmb/66.1.43
[4] Fiorini M, Bongianni M, Monaco S, et al. Biochemical characterization of prions. Prog Mol Biol Transl Sci, 2017; 150, 389−407.
[5] Castle AR, Gill AC. Physiological functions of the cellular prion protein. Front Mol Biosci, 2017; 4, 19.
[6] Lehmann S. The prion protein. J Soc Biol, 2002; 196, 309−12. doi:  10.1051/jbio/2002196040309
[7] Yang XW, Zhang Y, Zhang LH, et al. Prion protein and cancers. Acta Biochim Biophys Sin, 2014; 46, 431−40. doi:  10.1093/abbs/gmu019
[8] Hinton C, Antony H, Hashimi SM, et al. Significance of prion and prion-like proteins in cancer development, progression and multi-drug resistance. Curr Cancer Drug Targets, 2013; 13, 895−904. doi:  10.2174/156800961131300092
[9] Liang J, Bai FH, Luo GH, et al. Hypoxia induced overexpression of PrPC in gastric cancer cell lines. Cancer Biol Ther, 2007; 6, 769−74. doi:  10.4161/cbt.6.5.4001
[10] MacLea KS. What makes a prion: infectious proteins from animals to yeast. Int Rev Cell Mol Biol, 2017; 329, 227−76.
[11] Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol, 2011; 3, a006833.
[12] Taguchi Y, Lu L, Marrero-Winkens C, et al. Disulfide-crosslink scanning reveals prion-induced conformational changes and prion strain-specific structures of the pathological prion protein PrPSc. J Biol Chem, 2018; 293, 12730−40. doi:  10.1074/jbc.RA117.001633
[13] Gao ZX, Shi J, Cai LL, et al. Prion dimer is heterogenous and is modulated by multiple negative and positive motifs. Biochem Biophys Res Commun, 2019; 509, 570−6. doi:  10.1016/j.bbrc.2018.12.113
[14] Wei W, Shi Q, Zhang NS, et al. Expression of prion protein is closely associated with pathological and clinical progression and abnormalities of p53 in head and neck squamous cell carcinomas. Oncol Rep, 2016; 35, 817−24. doi:  10.3892/or.2015.4425
[15] Zhou L, Shang YL, Liu CH, et al. Overexpression of PrPc, combined with MGr1-Ag/37LRP, is predictive of poor prognosis in gastric cancer. Int J Cancer, 2014; 135, 2329−37. doi:  10.1002/ijc.28883
[16] Diarra-Mehrpour M, Arrabal S, Jalil A, et al. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor α-induced cell death. Cancer Res, 2004; 64, 719−27. doi:  10.1158/0008-5472.CAN-03-1735
[17] Marrone A, Re N, Storchi L. The effects of Ca2+ concentration and E200K mutation on the aggregation propensity of PrPC: a computational study. PLoS One, 2016; 11, e0168039. doi:  10.1371/journal.pone.0168039
[18] Muramoto T. Prion protein structure and its relationships with pathogenesis. Rinsho Shinkeigaku, 2003; 43, 813−6.
[19] Mishra R, Elgland M, Begum A, et al. Impact of N-glycosylation site variants during human PrP aggregation and fibril nucleation. Biochim Biophys Acta Proteins Proteom, 2019; 1867, 909−21. doi:  10.1016/j.bbapap.2019.03.010
[20] Paciotti R, Storchi L, Marrone A. An insight of early PrP-E200K aggregation by combined molecular dynamics/fragment molecular orbital approaches. Proteins, 2019; 87, 51−61. doi:  10.1002/prot.25621